Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01688999 · OUTCOME

Overall Survival

Cabozantinib for Advanced Urothelial Cancer · Source last updated 2022-10-18

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Median follow-up was 61.2 months

What was measured

Measure the timing from the study start until death.

Analysis population: 42/50 were analyzed in cohort 1 because 5 participants withdrew, 2 were taken off study for adverse events and 1 was ineligible. In cohort 2, 5/6 patients were analyzed because 1 withdrew; and in cohort 3, 10/13 patients were analyzed because 1 withdrew and 2 were taken off study due to adverse events.

Groups in this outcome

Cohort 1 - (Urothelial Progressive Disease)

Patients with bone-only urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.

Cohort 2 (Bone-only)

Patients with bone-only urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.

Cohort 3 (Rare Histologies)

Patients with non-transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 1 - (Urothelial Progressive Disease)42
Cohort 2 (Bone-only)5
Cohort 3 (Rare Histologies)10

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cohort 1 - (Urothelial Progressive Disease)8.1Not reported5.210.3Not reported
Cohort 2 (Bone-only)9.3Not reported4.612.5Not reported
Cohort 3 (Rare Histologies)5.8Not reported2.68.1Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5.2
        upper Limit
        10.3
        value
        8.1
      2. group Id
        OG001
        lower Limit
        4.6
        upper Limit
        12.5
        value
        9.3
      3. group Id
        OG002
        lower Limit
        2.6
        upper Limit
        8.1
        value
        5.8
denoms
  1. counts
    1. group Id
      OG000
      value
      42
    2. group Id
      OG001
      value
      5
    3. group Id
      OG002
      value
      10
    units
    Participants
description
Measure the timing from the study start until death.
dispersion Type
95% Confidence Interval
groups
  1. description
    Patients with bone-only urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.
    id
    OG000
    title
    Cohort 1 - (Urothelial Progressive Disease)
  2. description
    Patients with bone-only urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis.
    id
    OG001
    title
    Cohort 2 (Bone-only)
  3. description
    Patients with non-transitional cell carcinoma of the bladder, urethra, ureter, or renal pelvis.
    id
    OG002
    title
    Cohort 3 (Rare Histologies)
param Type
MEDIAN
population Description
42/50 were analyzed in cohort 1 because 5 participants withdrew, 2 were taken off study for adverse events and 1 was ineligible. In cohort 2, 5/6 patients were analyzed because 1 withdrew; and in cohort 3, 10/13 patients were analyzed because 1 withdrew and 2 were taken off study due to adverse events.
reporting Status
POSTED
time Frame
Median follow-up was 61.2 months
title
Overall Survival
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice